GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » 1-Year ROIIC %

Labcorp Holdings (Labcorp Holdings) 1-Year ROIIC % : 46.80% (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Labcorp Holdings's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was 46.80%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Labcorp Holdings's 1-Year ROIIC % or its related term are showing as below:

LH's 1-Year ROIIC % is ranked better than
73.11% of 212 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.38 vs LH: 46.80

Labcorp Holdings 1-Year ROIIC % Historical Data

The historical data trend for Labcorp Holdings's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings 1-Year ROIIC % Chart

Labcorp Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 172.42 1.24 -3.57 37.25

Labcorp Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.32 -0.01 -4.41 37.25 46.80

Competitive Comparison of Labcorp Holdings's 1-Year ROIIC %

For the Diagnostics & Research subindustry, Labcorp Holdings's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings's 1-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's 1-Year ROIIC % falls into.



Labcorp Holdings 1-Year ROIIC % Calculation

Labcorp Holdings's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( 935.8048 (Mar. 2024) - 2023.7876 (Mar. 2023) )/( 15671.2 (Mar. 2024) - 17995.9 (Mar. 2023) )
=-1087.9828/-2324.7
=46.80%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Labcorp Holdings  (NYSE:LH) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Labcorp Holdings 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Labcorp Holdings (Labcorp Holdings) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney officer: SVP, Chief Medical Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams director DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215